When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

The immunosuppressive agent mycophenolate is used extensively in kidney transplantation,
yet dosing strategy applied varies markedly from fixed dosing (“one-dose-fits-all”), to …

The goal of immunosuppressive therapy post-transplantation in pediatric renal transplant
recipients is to prevent acute and chronic rejection while minimizing drug side effects. Most …

Solid organ transplantation has transformed the lives of many children and adults by
providing treatment for patients with organ failure who would have otherwise succumbed to …

Immunosuppressant is a class of medicines that inhibit or decrease the intensity of the
immune response in the body. Most of these medications are used to allow the body less …

Immunosuppressive therapy is used in solid organ transplant treatment, and mycophenolic
acid (MPA) is one of the immunosuppressive drugs most used worldwide. It is a potent …

Background: Mycophenolic acid (MPA) exposure in pediatric patients with kidney transplant
receiving body surface area (BSA)–based dosing exhibits large variability. Several genetic …

Introduction: Mycophenolate mofetil (MMF) is an ester prodrug of the immunosuppressant
mycophenolic acid (MPA) and is recommended and widely used for maintenance …

We have reviewed current evidence on the therapeutic drug monitoring (TDM) of
mycophenolic acid (MPA) in relationship to drug efficacy and safety. The relationship …

Mycophenolate mofetil (MMF) has emerged as a new therapeutic option in steroid-
dependent nephrotic syndrome (SDNS). We conducted a phase II Bayesian trial of MMF in …